Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shun Tsunoda

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|February 12, 2025
[Efficacy of rituximab for idiopathic acquired pure red cell aplasia]Shuku Sato, Shun Tsunoda, Yotaro Tamai
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|April 7, 2022
[Plasmablastic myeloma initially presented with ascites]Shuku Sato, Shun Tsunoda, Wataru Kamata, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 5, 2025
[Efficacy and safety of romiplostim in aplastic anemia refractory or intolerant to immunosuppressive therapy with eltrombopag]Shuku Sato, Shun Tsunoda, Wataru Kamata, et al.
Blood Research|February 5, 2025
Real-world effectiveness and safety of rituximab and reduced-dose CHP with polatuzumab vedotin (pola-R-CHP) in patients aged > 80 years with diffuse large B-cell lymphoma: a retrospective analysisShuku Sato, Shun Tsunoda, Wataru Kamata, et al.
Frontiers in Medicine|June 20, 2022
Case Report: A Case of Myeloproliferative Neoplasm Complicated by Alopecia AreataYotaro Tamai, Shinichi Teshima, Shun Tsunoda, et al.
Annals of Hematology|March 23, 2023
Clinical significance of high-dose chemotherapy with autologous stem cell transplantation in the era of novel agents in patients older than 65 years with multiple myelomaShuku Sato, Shun Tsunoda, Teiko Kawahigashi, et al.
Mediterranean Journal of Hematology and Infectious Diseases|November 14, 2025
Dose-Attenuated-Polatuzumab Vedotine plus CHP vs. Dose-Attenuated -R-CHOP in Patients Aged ≥ 80 Years with Diffuse Large B-Cell Lymphoma: A Retrospective, Propensity Score-Matched Analysis Stratified by Simplified Frailty ScoreShuku Sato, Emi Sawazaki, Shun Tsunoda, et al.
International Journal of Hematology|March 9, 2025
Retrospective analysis of treatment discontinuation in minimal residual disease negative multiple myelomaShuku Sato, Emi Sawazaki, Shun Tsunoda, et al.
Respirology Case Reports|January 6, 2023
Obstructive shock due to a spontaneous haemothorax caused by primary lung cancerHiroe Aramaki, Kiyomitsu Fukaguchi, Hiroshi Yamagami, et al.
International Journal of Hematology|March 11, 2026
Efficacy and safety of romiplostim with horse anti-thymocyte globulin and cyclosporine in acquired aplastic anemiaShuku Sato, Emi Sawazaki, Shun Tsunoda, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|February 12, 2025
[Efficacy of rituximab for idiopathic acquired pure red cell aplasia]Shuku Sato, Shun Tsunoda, Yotaro Tamai
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|April 7, 2022
[Plasmablastic myeloma initially presented with ascites]Shuku Sato, Shun Tsunoda, Wataru Kamata, et al.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|March 5, 2025
[Efficacy and safety of romiplostim in aplastic anemia refractory or intolerant to immunosuppressive therapy with eltrombopag]Shuku Sato, Shun Tsunoda, Wataru Kamata, et al.
Blood Research|February 5, 2025
Real-world effectiveness and safety of rituximab and reduced-dose CHP with polatuzumab vedotin (pola-R-CHP) in patients aged > 80 years with diffuse large B-cell lymphoma: a retrospective analysisShuku Sato, Shun Tsunoda, Wataru Kamata, et al.
Frontiers in Medicine|June 20, 2022
Case Report: A Case of Myeloproliferative Neoplasm Complicated by Alopecia AreataYotaro Tamai, Shinichi Teshima, Shun Tsunoda, et al.
Annals of Hematology|March 23, 2023
Clinical significance of high-dose chemotherapy with autologous stem cell transplantation in the era of novel agents in patients older than 65 years with multiple myelomaShuku Sato, Shun Tsunoda, Teiko Kawahigashi, et al.
Mediterranean Journal of Hematology and Infectious Diseases|November 14, 2025
Dose-Attenuated-Polatuzumab Vedotine plus CHP vs. Dose-Attenuated -R-CHOP in Patients Aged ≥ 80 Years with Diffuse Large B-Cell Lymphoma: A Retrospective, Propensity Score-Matched Analysis Stratified by Simplified Frailty ScoreShuku Sato, Emi Sawazaki, Shun Tsunoda, et al.
International Journal of Hematology|March 9, 2025
Retrospective analysis of treatment discontinuation in minimal residual disease negative multiple myelomaShuku Sato, Emi Sawazaki, Shun Tsunoda, et al.
Respirology Case Reports|January 6, 2023
Obstructive shock due to a spontaneous haemothorax caused by primary lung cancerHiroe Aramaki, Kiyomitsu Fukaguchi, Hiroshi Yamagami, et al.
International Journal of Hematology|March 11, 2026
Efficacy and safety of romiplostim with horse anti-thymocyte globulin and cyclosporine in acquired aplastic anemiaShuku Sato, Emi Sawazaki, Shun Tsunoda, et al.
Pageof 2